Genmab (GMAB) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Genmab A/S, a leading biotechnology firm, announced that Baillie Gifford & Co now holds 4.99% of its shares, signaling a significant investment by the major shareholder. The company, renowned for its innovative antibody therapeutics and ambitious vision to revolutionize treatment for cancer and other serious diseases by 2030, emphasizes its strong international presence and a 25-year legacy of technological advancements in the biotech industry.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
